Hobby scored the first 5-star rating in North America. Photo via fly2houston.com

Houston travelers now have new bragging rights. William P. Hobby Airport has just scored a prestigious 5-Star Airport status in the Skytrax World Airport Star Rating for 2022. That makes Hobby the first airport in Texas, the U.S., and North America — and one of just 16 airports across the world to land the 5-star rating.

A little about this ranking: The Skytrax World Airport Star Rating is a global benchmark of quality evaluation for the aviation industry, a press release describes. All airports are rated between a 1-Star and 5-Star level after a detailed audit analysis of facilities and staff service to customers throughout all areas of front-line service.

In the new survey, Hobby soared in all 29 rating categories. The 5-Star Rating international Skytrax rating also highlighted the airport’s “wide range of substantial guest experience upgrades to the terminal interiors, passenger facilities, and customer service initiatives.”

Skytrax lauds recent Hobby improvements such as a new children’s play area, state-of-the-art restroom facilities, modern signage and information systems, a prayer room, and a new stage for live music performances.

Meanwhile, Houston’s other airport, George Bush Intercontinental, maintained its 4-Star rating for a fifth consecutive year, and boosted its score across the rating categories.

Houston Airports notes in a statement that construction continues to advance the international terminal redevelopment program, such as the planned Mickey Leland International Terminal, which aims to create two 5-star Houston airports.

“The entire Houston Airports team has worked tirelessly toward reaching this accomplishment at Hobby Airport,” Houston Airports director of aviation Mario Diaz said in a statement. “Providing the highest quality of customer service, exceptional amenities and cutting-edge facilities has earned us five stars at Hobby Airport and an improved 4-Star rating at Bush Airport, and now we owe it to our passengers to continue delivering excellence at every step of the airport experience.”

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.